John Flannery, President and CEO, GE Healthcare commented, “We have been working closely with our customers and observing market needs carefully and, as a result, have created an innovative solution improving access to biopharmaceuticals all over the world. We are providing a complete manufacturing solution faster than anyone else, which means that JHL is able to enter the market with high-quality pharmaceuticals responding to a real market need in record time.”
(1) FDA, 2015: Biosimilars are a type of biological product that are licensed (approved) by regulatory authorities because they are highly similar to an already-approved biological product, known as the biological reference product (reference product), and have been shown to have no clinically meaningful differences from the reference product.
Ad Statistics
Times Displayed: 50213
Times Visited: 1424 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
(2) Frost & Sullivan, Jan 2014: “Analysis of the Global Biosimilars Market”
(3) American Cancer Society, 2016: Cancer in China
(4) China Daily, 2015: 'Made in China 2025' plan unveiled
(5) GEN, 2015: The Top 25 Best-Selling Drugs of 2014 (a subscription required)
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About JHL Biotech
JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars.
JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. The JHL Center of Excellence in Taiwan does biosimilar pre-clinical and early-clinical phase R&D work. JHL’s facility in Wuhan, China will do commercial-scale manufacturing of biologic therapies. This infrastructure gives JHL the unique ability to manufacture its own product and execute contract orders for select clients. For more information, please visit www.jhlbiotech.com.
Back to HCB News
